Compare NGS & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGS | DNA |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 475.1M | 455.8M |
| IPO Year | 2006 | N/A |
| Metric | NGS | DNA |
|---|---|---|
| Price | $43.56 | $7.30 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | ★ $40.67 | $8.50 |
| AVG Volume (30 Days) | 82.6K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 14.60 | N/A |
| EPS | ★ 0.53 | N/A |
| Revenue | ★ $172,315,000.00 | N/A |
| Revenue This Year | $15.05 | N/A |
| Revenue Next Year | $9.52 | N/A |
| P/E Ratio | $82.83 | ★ N/A |
| Revenue Growth | ★ 9.94 | N/A |
| 52 Week Low | $22.72 | $5.37 |
| 52 Week High | $44.12 | $17.58 |
| Indicator | NGS | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 66.80 | 40.74 |
| Support Level | $32.52 | $5.93 |
| Resistance Level | N/A | $7.38 |
| Average True Range (ATR) | 1.59 | 0.82 |
| MACD | 0.28 | -0.27 |
| Stochastic Oscillator | 89.51 | 4.24 |
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.